Navigation Links
Ottawa researchers discover new combination therapy to kill cancer
Date:1/27/2014

OTTAWA, ON January 27, 2014 Cancer is the leading cause of death in Canada and is responsible for about 30% of all deaths, according to the Canadian Cancer Society. Despite the urgent need for new and effective drugs, it remains extremely difficult to develop anti-cancer therapies in a timely way. Researchers in Ottawa looked at how to leverage current experimental therapies, in different combinations, to speed the fight against cancer. Scientific evidence suggests a specific combination approach is effective, as published today in Nature Biotechnology.

"We are very excited about this novel combination approach and are looking to move this experimental therapy into clinical trials as soon as possible," said Dr. Robert Korneluk, distinguished professor at the University of Ottawa and senior scientist at the CHEO Research Institute. "I firmly believe that it's not a matter of 'if' this will help cancer patients but 'when' this therapy becomes a standard of care."

Worldwide evidence has already shown that two immunotherapies are promising. The first, SMAC Mimetics, is an IAP-based therapy that targets cancer-causing genes. IAPs were discovered at CHEO 19 years ago. The second, live virus therapies, or oncolytics, are a separate field of study booming in Ottawa. Both of these immunotherapies are in clinical trials now and although the results are encouraging, neither, as a stand-alone therapy, have yet to show substantial effects. That is until a team of scientists led by Dr. Korneluk discovered that combining SMAC Mimetics together with a live virus (or even other non-viral immune stimulators), results in a synergistic, or amplified, tumour-killing effect, which overcomes the limitation of either agent on its own.

"Our combination approach is quite different than standard chemotherapy treatments that can have significant negative side-effects," continued Dr. Korneluk. "Instead, we looked at combining two novel experimental cancer drugs that we already know work on the immune system. The results of our combination exceeded expectations and furthermore, no harm was done to the surrounding healthy tissue when we eradicated tumours."

In some cases, tumours required 10,000-times less virus to kill a cancer cell when a SMAC mimetic was added. The combined use of these two drugs could possibly save years of clinical development time, allowing for faster patient access to these drugs. The research team postulates that this combination approach is likely better suited for specific cancers and specific uses. For example, tumours which cannot be surgically removed but which can be injected with a cancer-killing virus are good candidates.


'/>"/>

Contact: Adrienne Vienneau
avienneau@cheo.on.ca
613-737-7600 x4144
Children's Hospital of Eastern Ontario Research Institute
Source:Eurekalert

Related biology news :

1. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
2. Cleveland Clinic researchers discover process that turns good cholesterol bad
3. Researchers discover potential drug targets for early onset glaucoma
4. Researchers identify innate channel that protects against pain
5. Combustion continues to draw researchers to space station
6. Curtin researchers to hide our splashes from sharks
7. Researchers discover how heart arrhythmia occurs
8. Researchers collaborate to reduce effects of the aging eye
9. 1 step at a time, researchers learning how humans walk
10. Researchers discover that coevolution between humans and bacteria reduces gastric cancer risk
11. Researchers identify key components linking circadian rhythms and cell division cycles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... May 25, 2016 , ... ... variety of fracture-specific plating options designed to address fractures of the distal tibia ... solutions. , The Acumed Ankle Plating System 3 is composed of seven plate ...
(Date:5/25/2016)... ... ... Lady had been battling arthritis since the age of two and at ... owner Hannah sought the help of Dr Jeff Christiansen of Superior Veterinary Surgical ... and help with the pain of Lady’s arthritis. Dr Christiansen suggested that in conjunction ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... re-branded identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for ... and image analysis. The re-branding components include a crisp, refreshed logo and a ...
(Date:5/23/2016)... , May 23, 2016 - Leading CRO,s ... - Frontage Implement a Single Platform to Manage End-to-end ... Traceability Within the Bioanalytical lab Frontage Laboratories, a full-service ... States and China , has selected ... facilities. In addition to serving as the global electronic lab notebook ...
Breaking Biology Technology: